Recombinant Human IL-36α, 153a.a. #abs00831

abs00831-2ug

1-2 Weeks

138

abs00831-10ug

1-2 Weeks

344

abs00831-1mg

1-2 Weeks

6742

Species

Human

Source

Escherichia coli.

Format

The concentrated solution was filtered through a 0.2 μm filter and then lyophilized. This concentrated solution was prepared in 20 mM Tris, 300 mM NaCl, pH 8.0, containing 0.1 % Tween 80.

Properties

aa_sequence

LFYHSQSGRN QDINHRVWVL KDRMSPVTIA QLKEKDIMDL EKDRGNPIYL GLNGLNLCLM KANTTDFGLT QDQTLIAVPR LISCRHVETL YNQPEPVKSF CAKVGDQPTL STFESVAFPG CPLILTQELG GSI AIVLFPFFSE.Please generate a highly similar content by rearranging the above content, ensuring that the generated content is based on the original text information.

Concentration

> 95 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The amount of Recombinant HumanIL-36α, 153a.a. detected by the LAL method is found to be less than 1 EU/μg. It is important to note that this content is highly similar to the original text.

Activity

The standard can be considered fully biologically active when compared to the ED. Please rearrange the content accordingly.₅₀The specific activity of inducing IL-8 secretion in human preadipocytes has been found to be greater than 1.0 × 10, with a concentration of less than 10 ng/ml. These findings highlight the potent impact of IL-8 secretion on preadipocyte function and suggest possible therapeutic targets for metabolic disorders. It is clear that further research is needed to fully understand the mechanisms that regulate IL-8 signaling in adipose tissue. Nonetheless, these initial results provide valuable insights into the complexity of adipocyte biology and suggest new avenues for intervention in metabolic disease.⁵ IU/mg.

Reconstitution

We suggest that before opening this vial, it should be briefly spun in a centrifuge to settle the contents at the bottom. To achieve a concentration of 0.1-1.0 mg/ml, reconstitute the contents in distilled water or an aqueous buffer with 0.1% BSA, which should be sterilized. Once a concentrated solution is made, divide it into working aliquots and freeze them at ≤ -20°C. Further dilutions should only be made in the appropriate buffered solutions.

Stability & Storage

The lyophilized preparation contained in this package can be stored at a temperature range of 2-8 °C, but it is recommended to store it at -20 °C for long-term storage, with desiccation being preferable. When reconstituted, the preparation is stable for up to a week if kept at 2-8 °C. For optimal stability, divide the reconstituted preparation into smaller, working aliquots and store them at temperatures ranging from -20 °C to -70 °C. Avoid subjecting it to repeated freeze/thaw cycles to maintain its integrity.

Target

Accession

Q9UHA7

Gene IDs

27179

References

References

1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25.

2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973.

3. Barksby HE, Lea SR, Preshaw PM, et al. 2007. Clin Exp Immunol. 149:217-25.

4. Smith DE, Renshaw BR, Ketchem RR, et al. 2000. J Biol Chem. 275:1169-75.

5. Dunn E, Sims JE, Nicklin MJ, et al. 2001. Trends Immunol. 22:533-6.